Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer

P E Postmus; N H Mulder; J C Grampel; W H Meyers; H H Berendsen

doi:10.1016/0277-5379(87)90156-8

Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer

Eur J Cancer Clin Oncol. 1987 Aug;23(8):1207-8. doi: 10.1016/0277-5379(87)90156-8.

Authors

P E Postmus¹, N H Mulder, J C Grampel, W H Meyers, H H Berendsen

Affiliation

¹ Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands.

PMID: 2820748
DOI: 10.1016/0277-5379(87)90156-8

Abstract

Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC.

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Aziridines / administration & dosage
Aziridines / adverse effects
Aziridines / therapeutic use*
Azirines / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Drug Evaluation
Female
Humans
Leukopenia / chemically induced
Lung Neoplasms / drug therapy*
Male
Middle Aged
Thrombocytopenia / chemically induced

Substances

Antineoplastic Agents
Aziridines
Azirines
1,3-diaziridino-2,4,6-triaza-1,3,5,5-tetraaminomethyl-1,3,5-triphosphorin